ClinicalTrials.gg
CompletedNCT07186426Updated Aug 26, 2026

A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients for Postoperative Pain Treatment in Orthopedic Surgery

A Phase 3 interventional study of HSK21542 and Placebo in Postoperative Pain Management, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 248 studies in Pain, Postoperative with a site in China — 78 open to participants now, 80 under way, 3 of them phase 3. Pain, Postoperative · China.

Enrollment
17th of 205
405 · median 132
Started
2025
with 28 others
Phase 3
8 of 248
none open now
Registered
196th of 248
by date

Among the 248 studies in Pain, Postoperative with a site in China, this one is the 17th largest by enrollment of the 205 interventional ones that give a count, is one of 29 that started in 2025, is one of 8 in phase 3, and was the 196th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

78 of the 248 studies in Pain, Postoperative with a site in China are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Pain, Postoperative with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, placebo/active-controlled study. 405 subjects undergoing orthopedic surgery under general anesthesia are planned to be enrolled and randomized into the HSK21542 group, morphine group, and placebo group.

03

Conditions studied

  • Postoperative Pain Management

Browse trials for

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old ≤ age ≤74 years old, regardless of gender;
  • 18 kg/m2≤≤32 kg/m2,meet the weight range specified in the protocol;
  • (ASA) grade ⅰ-ⅲ;
  • Accept hip replacement under general anesthesia;
  • Within 4 hours after the end of surgery, NRS≥4 in the resting state at any time;
  • Fully understand and voluntarily participate this trial, and sign the form;

Exclusion criteria

Exclusion Criteria:

  • Patients with allergy to opioids or any component of the trial drug;
  • Patients with a history of severe cardiovascular and cerebrovascular diseases, ,and psychiatric disorders;
  • Last use of opioid or non-opioid analgesics less than 5 half-lives or the duration of drug efficacy prior to randomization; use of drugs with unclear half-lives that may affect analgesic efficacy within 7 days prior to randomization, or last use of drugs affecting analgesic efficacy less than 5 half-lives prior to randomization, as well as Chinese herbal medicines or proprietary Chinese medicines deemed by the investigator as potentially impacting the evaluation of efficacy and safety;
  • Continuous use of opioid analgesics for more than 7 days for any reason within 30 days prior to screening;
  • Laboratory test results during the screening period meeting any of the following criteria: 1) Significantly abnormal hematology results; 2) Significantly abnormal test results; 3) Significantly abnormal liver or kidney function; 4) Significantly abnormal fasting blood glucose;
  • Positive test results during the screening period for surface antigen (HBsAg), antibody (HCVAb), syphilis antibody, or (HIV) antibody;
  • A history of drug, drug, and/or alcohol abuse;
  • Participate in any clinical trail within 30 days;
  • Pregnant or lactating female subjects;
  • Subjects of who are unwilling to use throughout the study period or plan to become pregnant within 3 months after the study.;
  • Subjects with any other factor considered by the investigator to be ineligible for participation in the trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    HSK21542

    Patients administrated with HSK21542

    Drug: HSK21542

  • Placebo comparator
    Placebo control

    Patients administrated with placebo

    Drug: Placebo

  • Active comparator
    Actice control

    Patients administrated with morphine

    Drug: morphine

Interventions

  • Patients administrated with HSK21542

  • DrugPlacebo

    Patients administrated with placebo

  • Patients administrated with morphine

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity Differences (SPID)

    Sum of Pain Intensity Differences (SPID) of each group

    Time frame: 48 hours

Secondary outcomes

  1. Proportion of subjects experiencing nausea

    Proportion of subjects experiencing nausea of each group

    Time frame: 48 hours

  2. Proportion of subjects experiencing vomit

    Proportion of subjects experiencing vomit of each group

    Time frame: 48 hours

  3. Sum of Pain Intensity Differences (SPID) in other time frame

    Sum of Pain Intensity Differences (SPID) in other time frame

    Time frame: 0-8 hours, 0-24 hours, 24-48 hours

  4. Number of times rescue analgesic medications were administered.

    Number of times rescue analgesic medications were administered.

    Time frame: 48 hours

  5. Total morphine consumption

    Total morphine consumption of each group

    Time frame: 48 hours

07

Study locations

2 sites
  • Xuanwu Hospital Capital Medical University
    Beijing, Beijing Municipality, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Feb 2026, 6 months.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 6 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Sep 22, 2025
StartActual
Aug 5, 2025
Primary completionActual
Feb 24, 2026
CompletionActual
Feb 24, 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07186426
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Aug 5, 2025
Primary completion
Feb 24, 2026
Completion
Feb 24, 2026
Last update
Aug 26, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anrikefon

Start the discussion